ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Lonza will supply Oasmia Pharmaceutical, a Swedish oncology specialist, with TRXE-002-01, the active ingredient in Cantrixil, Oasmia’s investigational drug candidate for ovarian cancer. Lonza will provide kilogram-scale synthesis, purification, and stability testing of the molecule for clinical supply at its facility in Nansha, China. Oasmia licensed Cantrixil from the Australian firm Kazia Therapeutics after a successful Phase 1 trial.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X